课题基金 / 基金详情

项目摘要

项目成果

David Kokel的其他基金

相似基金

相关文献

中文摘要
翻译
描述:神经系统疾病是人类所有疾病中最具破坏性和负担的疾病之一,但它们仍然是治疗最差的疾病之一。对于大多数中枢神经系统疾病,我们对潜在的生物学知识了解很少,而且还没有确定有效的治疗靶点。具有讽刺意味的是,基因组中最容易下药的蛋白质类别在神经系统中有很高的代表性,并有助于神经系统疾病的病理。如果他们的神经系统功能得到更好的了解,其中一些无疑会成为很好的治疗靶点。不幸的是,为这些特征不佳的基因分配功能仍然是相当具有挑战性的,特别是那些参与中枢神经系统复杂工作的基因。基于细胞的体外分析完全不足以对神经系统中的基因功能进行建模。需要可扩展的、负担得起的方法来系统地扰乱体内的基因功能,并广泛评估其对神经系统的影响。斑马鱼提供了一个独特的机会来阐明可用药基因组的基因。在过去的五年里,新的工具使得对斑马鱼基因组进行有针对性的改变成为可能。与此同时,已经开发了12种新的行为分析方法,可以广泛地评估基因或小分子对神经系统的影响。该项目将这些新的基因组操作技术与高通量行为图谱相结合,以表征可用药基因组的基因。使用CRISPR-CAS系统将敲除斑马鱼中感兴趣的基因,并将对突变动物进行一系列全面的行为测试,以评估对神经系统的影响。在平行实验中,斑马鱼基因组中的相同基因将被一种新型的可视化/消融盒取代,从而能够对体内表达模式进行详细的4D可视化。最后,一个独特的计算资源将使识别感兴趣蛋白质的候选配体(探针)变得容易。这些概念验证实验将集中在15个基因上,既包括特征良好的例子,也包括特征不佳的例子,并将为更全面地探索可用药基因组铺平道路。目的:目的1.研究可用药基因组中基因的神经系统功能。目的2.开发可视化和操纵可用药基因组基因的工具。目的3.确定可用药基因组中基因的候选配体。通过提供详细的敲除表型、体内表达模式和每个感兴趣基因的小分子探针,我们希望推进阐明可药物基因组基因的重要目标。
英文摘要
DESCRIPTION: Diseases of the nervous system are among the most devastating and burdensome of all human illnesses, yet they remain among the most poorly treated. For most CNS disorders, we understand the underlying biology poorly, and validated therapeutic targets have not been identified. Ironically, the most druggable protein classes in the genome are highly represented in the nervous system and contribute to the pathology of nervous system disorders. If their nervous system functions were better understood, some would undoubtedly be excellent therapeutic targets. Unfortunately, it remains quite challenging to assign functions to these poorly characterized genes, especially those involved in the complex workings of the CNS. Cell-based, in vitro assays are wholly inadequate to model the functions of genes in the nervous system. Scalable, affordable approaches are needed for systematically disrupting gene function in vivo and assessing the effects on the nervous system broadly. Zebrafish provide a unique opportunity to illuminate the genes of the druggable genome. Over the past five years, new tools have made it possible to make targeted changes in the zebrafish genome. Simultaneously, twelve new behavioral assays have been developed that can assess broadly the effects of genes or small molecules on the nervous system. This project combines these novel techniques for genome manipulation with high-throughput behavioral profiling to characterize genes of the druggable genome. Genes of interest will be knocked out in zebrafish using CRISPR-Cas systems, and the mutant animals will be subjected to a comprehensive panel of behavioral assays to assess effects on the nervous system. In parallel experiments, the same genes will be replaced in the zebrafish genome by a novel visualization/ablation cassette, enabling detailed 4D visualization of the in vivo expression patterns. Finally, a unique computational resource will enable facile identification of candidate ligands (probes) for the proteins of interest. These proof- of-concept experiments will focus on 15 genes selected to include both well- and poorly-characterized examples and will pave the way for a more comprehensive exploration of the druggable genome. Aims include: Aim 1. To characterize the nervous system functions of genes in the druggable genome. Aim 2. To develop tools for visualizing and manipulating the genes of the druggable genome. Aim 3. To identify candidate ligands for genes in the druggable genome. By providing detailed knock-out phenotyping, in vivo expression patterns, and a small molecule probe for each of the genes of interest, we hope to advance the important goal of illuminating the genes of the druggable genome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Scalable in vivo tools for annotating and manipulating the druggable genome
  • 批准号:
    8898228
  • 项目类别:
  • 资助金额:
    $44.9万
  • 财政年份:
    2014
  • 负责人:
    David Kokel
  • 依托单位:
Behavior-based chemical screening for GABAergic and startle modifying drugs
Behavior-based chemical screening for GABAergic and startle modifying drugs
  • 批准号:
    8547973
  • 项目类别:
  • 资助金额:
    $34.8万
  • 财政年份:
    2013
  • 负责人:
    David Kokel
  • 依托单位:
Behavior-based chemical screening for GABAergic and startle modifying drugs
海外基金